News
TELA
5.67
+1.07%
0.06
Weekly Report: what happened at TELA last week (0318-0322)?
Weekly Report · 3d ago
TELA Bio Price Target Maintained With a $15.00/Share by JMP Securities
Dow Jones · 6d ago
JMP Securities Reiterates Market Outperform on TELA Bio, Maintains $15 Price Target
Benzinga · 6d ago
TELA Bio Is Maintained at Overweight by Piper Sandler
Dow Jones · 6d ago
TELA Bio Price Target Cut to $12.00/Share From $15.00 by Piper Sandler
Dow Jones · 6d ago
Piper Sandler Maintains Overweight on TELA Bio, Lowers Price Target to $12
Benzinga · 6d ago
Piper Sandler Initiates a Buy Rating on TELA Bio (TELA)
TipRanks · 03/22 11:18
Analysts Offer Insights on Healthcare Companies: TELA Bio (TELA) and Vor Biopharma (VOR)
TipRanks · 03/22 04:30
TELA Stock Earnings: TELA Bio Misses EPS, Beats Revenue for Q4 2023
TELA Bio reported earnings per share of -53 cents for the fourth quarter of 2023. The company reported revenue of $17.00 million. This was 3.71% better than the analyst estimate for revenue. TELA bio also reported results for the third quarter of 2018.
Investorplace · 03/22 00:53
TELA Bio, Inc. (TELA) Reports Q4 Loss, Tops Revenue Estimates
NASDAQ · 03/21 21:30
TELA Bio Inc reports results for the quarter ended in December - Earnings Summary
TELA Bio Inc reports results for the quarter ended in December. Revenue rose 46.3% to $17.00 million from a year ago. The company reported a quarterly adjusted loss of 53 cents per share. The mean expectation of five analysts was for a loss of 43 cents.
Reuters · 03/21 21:01
TELA Bio Announces Investor Update and Hernia Mesh Launch
TipRanks · 03/21 20:33
Recap: TELA Bio Q4 Earnings
TELA Bio reported its Q4 earnings on March 21, 2024. The company missed estimates by $0.53. TELa Bio's revenue was up $5.38 million from the same period last year. The stock dropped 19.0% after the announcement.
Benzinga · 03/21 20:20
TELA Bio Q4 2023 GAAP EPS $(0.53) Misses $(0.44) Estimate, Sales $16.998M Beat $16.392M Estimate
TELA Bio reported quarterly losses of $0.53 per share. The company reported quarterly sales of $16.998 million. Sales are up 46.26 percent over the same period last year. The firm missed the analyst consensus estimate by 20.45 percent.
Benzinga · 03/21 20:16
TELA Bio GAAP EPS of -$0.53 misses by $0.10, revenue of $17M beats by $0.61M
TELA Bio, Inc. Reports Q4 GAAP EPS of -$0.53 misses by $0.10, revenue of $17M beats by $ 0.61M. The company is expected to report its quarterly results on March 21, 2024.
Seeking Alpha · 03/21 20:13
BRIEF-TELA Bio Q4 Revenue USD 16.998 Million Vs. IBES Estimate USD 16.4 Million
TELA Bio reports Q4 revenue of $16.998 million. The company says it expects FY revenue to be in the range of $74 million to $76 million. Q4 basic EPS was $0.53; Q4 income was $12.4 million.
Reuters · 03/21 20:05
Press Release: TELA Bio Achieves Record Fourth -2-
Ir@telabio.com TELA Bio, Inc. Total current assets: $71,726 Cash and cash equivalents, net of restricted cash and other assets. Total assets as of December 31, 2017: $46.7 million The company has a total of $1.8 billion in cash and cash equivalent assets. The company's total assets are expected to rise to $100 million by the end of the year.
Dow Jones · 03/21 20:05
*TELA Bio 4Q Rev $17M >TELA
Dow Jones · 03/21 20:05
Press Release: TELA Bio Achieves Record Fourth Quarter and Full Year 2023 Revenues and Reports Complete Financial Results
TELA Bio Achieves Record Fourth Quarter and Full Year 2023 Revenues and Reports Complete Financial Results. The company reports growth of 46% and 41% for the fourth quarter and full year ended December 31, 2023. The company is focused on providing innovative soft-tissue reconstruction solutions for hernia repairs.
Dow Jones · 03/21 20:05
*TELA Bio 4Q Loss/Shr 53c >TELA
Dow Jones · 03/21 20:05
More
Webull provides a variety of real-time TELA stock news. You can receive the latest news about Tela Bio, Inc. through multiple platforms. This information may help you make smarter investment decisions.
About TELA
TELA Bio, Inc. is a commercial-stage medical technology company. The Company is focused on providing soft-tissue reconstruction solutions that optimize clinical outcomes by prioritizing the preservation and restoration of the patient’s own anatomy. The Company's first portfolio of products, the OviTex Reinforced Tissue Matrix (OviTex) is designed for hernia repair and abdominal wall reconstruction by combining the benefits of biologic matrices and polymer materials. The Company's OviTex products include OviTex 1S, OviTex 2S, and OviTex LPR. The OviTex products are sterile reinforced tissue matrices derived from ovine rumen with either polypropylene or polyglycolic acid (PGA). The Company's second portfolio of products, the OviTex PRS Reinforced Tissue Matrix (OviTex PRS), addresses unmet needs in plastic and reconstructive surgery. OviTex PRS is indicated for use in implantation to reinforce soft tissue where weakness exists in patients requiring soft-tissue repair.